Basel, Basel, Switzerland
Since 2021: Group Head in Analytical Development Bioassays. Since April 2016: Heading three Labs in Early Phase Analytical Development at Novartis Pharma R&D. Development of bioanalytical assays for biologics (therapeutic proteins (non-IgG), fusion proteins, bispecifics, monoclonal Abs, cell & gene therapy). Development and GMP testing in Early Phase, Analytical Project Lead (CMC) - Design of analytical strategy for biologics. Since April 2010: Lab Head Bioanalytics at Novartis Pharma, R&D, Analytics of therapeutic antibodies/biologics, GMP. ELISA assays, cell-based binding and functional assays, qPCR, highmolecular weight impurities. Until april 2010:Head of Assay Development, cell-free electrophysiology (SSM, SURFE2R), molecular pharmacology of membrane transport proteins and ion channels, pre-clinical R&D, project management, customer relations. Specialties: Method and Assay development. Drug Development (GMP) as well as Research. Analytics and medium throughput Screening. Membrane biology and proteins (transporter, ion channels, pumps, G-proteins), Membrane protein complexes. CMC and Development of biologics / therapeutic antibodies. Analytical Project Lead. Molecular pharmacology, enzymology, immunology, cell-free electrophysiology. Protein-protein interactions, split-ubiquitin and yeast two hybrid.
Heading three Labs in Early Phase Analytical Development, Bioanalytics, Analytical Project Lead (CMC).
Lab Head and Functional Lead in Bioanalytics, Early and Late Phase Development.
EU project Associoport: Development and Application of the yeast mating-based Split Ubiquitin System for systematic screening for membrane protein-protein interactions. EU project Effexport: Optimizing the expression of membrane proteins in yeast.
Biochemical, cellular and molecular characterization of heterotrimeric G-protein complexes in plants.